if someone funds it, I have no problem as a shareholder. The FDA has not budged in approving rem_l for emergency use, in a ‘pandemic environment’ .
You won’t find any conspiracy with me, but this tells me the FDA is not convinced. Furthermore, Norvatis walked away from it as well.
Lets all focus on the information in hand and what the market is telling us. ARDS & agvhd is not the FDA’s favourite. MSB can’t keep on raising money, there are consequences with that. MSB is in enough debt as it is. MSB should move on and Stick to Heart and Back. MSB have the support for these two conditions, if they require more money to complete more trials.
That’s my opinion.
Next minute, FDA approves ARDS and agvhd.
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-47
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.005(0.54%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 91.5¢ | $1.473M | 1.596M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 32370 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 60258 | 5 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |